Add as a preferred source on GoogleDiaMedica Expects $34.9 Million to Fund Planned Operations Into Q4 2027
The company held $34.9 million in cash, cash equivalents and short-term investments on Sept. 30. A ReMEDy2 interim review is expected in Q1 2027.
DiaMedica Therapeutics expects its Sept. 30 financial resources to fund planned research and operations into Q4 2027, with an interim ReMEDy2 review expected in the first quarter of 2027.
The company’s quarter-end holdings totaled $34.9 million across cash, cash equivalents and short-term investments. Its estimate is based on current plans for research studies and operating needs.
ReMEDy2 interim results are expected to go before a Data Safety Monitoring Board in Q1 2027. Management identified a lack of drug effect as grounds to stop the study for futility. If the trial continues, its final enrollment target could range from 300 to 728 participants.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.